-
EGFR inhibitor development home: target degradation
Time of Update: 2021-08-10
Generations of EGFR-TKIs have brought us unlimited imagination, but cancer cells will always come back due to mutations and drug resistance .
-
Junshi Biology JS014 Injection Obtained the Notification of Acceptance of Drug Clinical Trial Application
Time of Update: 2021-08-10
The active ingredient of JS014 injection is recombinant interleukin 21-anti-human serum albumin (HSA) single-domain antibody fusion protein.
The half-life of IL-21 is significantly prolonged by fusion of anti-HSA single-domain antibody .
-
Target mitochondrial dysfunction!
Time of Update: 2021-08-10
Poxel SA and its partner Sumitomo Dainippon Pharma recently announced that Twymeeg (imeglimin hydrochloride, 500mg tablets) has been approved in Japan for the treatment of type 2 diabetes .
-
A large number of drugs are transferred out of medical insurance (list attached)
Time of Update: 2021-08-10
In accordance with the spirit of the document, in order to complete the three-year digestion of the non-national medical insurance drug list in the current drug catalog in Tianjin, after combing and comparing the occurrence of drug medical insurance costs and drug purchases, the second batch of excluded items was formulated and released, including a total of 155 Varieties .
-
New GlyT1 inhibitor BI 425809 is included in China's breakthrough treatment varieties
Time of Update: 2021-08-10
According to reports, Boehringer Ingelheim has planned to initiate a phase 3 clinical trial of BI 425809 to evaluate the safety and effectiveness of the drug in improving the cognition of adult patients with schizophrenia .
-
Chinese patient registration study meets expectations!
Time of Update: 2021-08-10
Research data shows that pratinib capsules have shown superior and long-lasting anti-tumor activity in Chinese patients with advanced or metastatic transfection rearrangement (RET) mutant medullary thyroid carcinoma (MTC) that require systemic treatment.
-
In the first half of 2021, these 11 Hillhouse invested biomedical companies have officially IPO!
Time of Update: 2021-08-10
According to reports, Century Therapeutics’ pre-clinical R&D projects include a variety of induced pluripotent stem cell-derived CAR-iT and CAR-iNK cell products, which are intended to be developed for the treatment of blood cancers and solid tumors .
-
Understand the two major drug traceability code specification documents in one article
Time of Update: 2021-08-10
The highlights of "Pharmaceutical Traceability Code Printing Regulations"The drug traceability code, like the electronic ID number of the drug, refers to the code used to uniquely identify the drug sales packaging unit, and consists of a series of numbers, letters and/or symbols .
-
Cooperation and innovation go hand in hand to speed up the overseas development of Chinese medicine
Time of Update: 2021-08-10
Figure 1: 2015-2019 exports of traditional Chinese medicine productsSource: China Chamber of Commerce for Import and Export of Medicines and Health Products, Customs StatisticsFrom the perspective of export commodity structure, plant extracts accounted for the highest proportion, mainly exported to the United States, used in the production of dietary supplements and food additives, and fluctuated under the influence of trade frictions; followed by Chinese herbal medicines and decoction pieces, and exported to major markets such as Japan and South Korea.
-
One year later, the clinical remission rate was significantly improved. AbbVie JAK inhibitor reached the phase 3 clinical endpoint
Time of Update: 2021-08-10
AbbVie announced today that its JAK inhibitor upadacitinib has achieved the primary and all secondary endpoints of clinical remission in a Phase 3 clinical trial of maintenance therapy for the treatment of ulcerative colitis .
com/news/press- releases/upadacitinib-rinvoq-met-primary-and-all-secondary-endpoints-in-52-week-phase-3-maintenance-study-in-ulcerative-colitis-patients.
-
Highlights of the new regulations in July: Guangxi and Guizhou Traditional Chinese Medicine Regulations are officially implemented
Time of Update: 2021-08-09
Guangxi: Promote the development of Chinese medicine The "Regulations of Guangxi Zhuang Autonomous Region on Traditional Chinese Medicine" came into effect on July 1 .
-
No price war!
Time of Update: 2021-08-09
51 chain pharmacies in Shanghai declare that they will not fight price wars51 chain pharmacies in Shanghai declare that they will not fight price warsRecently, the Shanghai Pharmaceutical Commerce Industry Association issued the "Proposal on Strengthening Compliance with Drug Sales Price Regulations" (hereinafter referred to as the "Proposal") to drug retail companies in the city, aiming to regulate the price order of the drug retail market .
-
"Implementation Measures for Early Resolution Mechanisms for Drug Patent Disputes (Trial)" is here!
Time of Update: 2021-08-09
The registered and published relevant patent information serves as the basis for the patent declaration made by the applicant for the listing registration of chemical generic drugs, Chinese medicines with the same name and the same prescription, and biosimilars .
-
The General Administration of Markets publishes 11 red lines for pharmacies, don’t touch
Time of Update: 2021-08-09
Prices are illegal, and new penalties for retail pharmacies are coming, involving clear price marking, price bidding, price fraud. . . The General Administration of Markets issued a document to severe
-
Zhongsheng Pharmaceutical's new drug application for the treatment of squamous non-small cell lung cancer with Paampril has been accepted
Time of Update: 2021-08-09
. A few days ago, Pianpril has passed the new real-time tumor review (RTOR) policy for the third-line treatment of metastatic nasopharyngeal carcinoma, and submitted a biologics license application (BLA) to the US FDA .
-
The medicinal materials made a nine-yuan price difference and a fine of 100,000 yuan. Why did the warehouse become the hardest hit area?
Time of Update: 2021-08-09
Pharmaceutical companies all know these temperature and humidity requirements, and our common reagents and prepared test solutions will not be kept in the warehouse all the time .
-
Danaher Life Sciences and WuXi Biologics jointly launch industry initiatives and release biopharmaceutical solutions
Time of Update: 2021-08-09
A few days ago, the Biopharmaceutical Ecosystem Innovation and Cooperation Summit jointly organized by Danaher Life Sciences and WuXi Biologics, with the China Biochemical and Pharmaceutical Industry Association as the guiding unit, was grandly held at the Jumeirah Himalayas Hotel in Shanghai .
-
Biopharmaceutical investment is seriously "involved" KRAS G12C hot targets are too crowded!
Time of Update: 2021-08-09
As long as biopharmaceutical talents have bold and reasonable innovative thinking, they can open up new fields for the needs of patients and develop original innovative drugs at low cost and high efficiency .
-
This year, the price of the original research of the new hyperkalemia drug ``Zirconium Cyclosilicate Sodium Powder'' will be reduced
Time of Update: 2021-08-09
On July 1, AstraZeneca voluntarily applied to lower the online price of "Sodium Zirconium Cyclosilicate Powder" from the previous 486 yuan to 340.
Every year before medical insurance negotiations, many new drugs will actively lower their online prices.
-
Ranking of 39 pharmaceutical companies in terms of productivity per capita of pharmaceutical representatives
Time of Update: 2021-08-09
According to the July issue of the Japanese Medical Information Express magazine, the highest per capita productivity of pharmaceutical representatives in Japan can reach 1 billion yen and the lowest is 70 million days.
